SEARCH

SEARCH BY CITATION

References

  • Abelsson, J., Merup, M., Birgegard, G., Weisbjerrum, O., Brinch, L., Brune, M., Johansson, P., Kauppila, M., Lenhoff, S., Liljeholm, M., Malm, C., Remes, K., Vindelov, L. & Andreasson, B. (2011) The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries. Bone Marrow Transplantation, 47, 380386.
  • Alchalby, H., Badbaran, A., Zabelina, T., Kobbe, G., Hahn, J., Wolff, D., Bornhauser, M., Thiede, C., Baurmann, H., Bethge, W., Hildebrandt, Y., Bacher, U., Fehse, B., Zander, A.R. & Kroger, N. (2010a) Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood, 116, 35723581.
  • Alchalby, H., Badbaran, A., Bock, O., Fehse, B., Bacher, U., Zander, A.R. & Kroger, N. (2010b) Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT. Bone Marrow Transplantation, 45, 14041407.
  • Bacigalupo, A., Soraru, M., Dominietto, A., Pozzi, S., Geroldi, S., Van Lint, M.T., Ibatici, A., Raiola, A.M., Frassoni, F., De Stefano, F., Verdiani, S., Casarino, L. & Barosi, G. (2010) Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplantation, 45, 458463.
  • Ballen, K.K., Shrestha, S., Sobocinski, K.A., Zhang, M.J., Bashey, A., Bolwell, B.J., Cervantes, F., Devine, S.M., Gale, R.P., Gupta, V., Hahn, T.E., Hogan, W.J., Kroger, N., Litzow, M.R., Marks, D.I., Maziarz, R.T., McCarthy, P.L., Schiller, G., Schouten, H.C., Roy, V., Wiernik, P.H., Horowitz, M.M., Giralt, S.A. & Arora, M. (2010) Outcome of transplantation for myelofibrosis. Biology of Blood and Marrow Transplantation, 16, 358367.
  • Barbui, T., Barosi, G., Birgegard, G., Cervantes, F., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H.C., Hehlmann, R., Hoffman, R., Kiladjian, J.J., Kroger, N., Mesa, R., McMullin, M.F., Pardanani, A., Passamonti, F., Vannucchi, A.M., Reiter, A., Silver, R.T., Verstovsek, S. & Tefferi, A. (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. Journal of Clinical Oncology, 29, 761770.
  • Barosi, G., Bergamaschi, G., Marchetti, M., Vannucchi, A.M., Guglielmelli, P., Antonioli, E., Massa, M., Rosti, V., Campanelli, R., Villani, L., Viarengo, G., Gattoni, E., Gerli, G., Specchia, G., Tinelli, C., Rambaldi, A. & Barbui, T. (2007) JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood, 110, 40304036.
  • Barosi, G., Mesa, R.A., Thiele, J., Cervantes, F., Campbell, P.J., Verstovsek, S., Dupriez, B., Levine, R.L., Passamonti, F., Gotlib, J., Reilly, J.T., Vannucchi, A.M., Hanson, C.A., Solberg, L.A., Orazi, A. & Tefferi, A. (2008) Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia, 22, 437438.
  • Berneman, Z.N., Anguille, S., Van Marck, V., Schroyens, W.A. & Van Tendeloo, V.F. (2010) Induction of complete remission of acute myeloid leukaemia by pegylated interferon-alpha-2a in a patient with transformed primary myelofibrosis. British Journal of Haematology, 149, 152155.
  • Boström, L., Ringdén, O., Jacobsen, N., Zwaan, F. & Nilsson, B. (1990) A European multicenter study of chronic graft-versus-host disease. The role of cytomegalovirus serology in recipients and donors, acute graft-versus-host disease and splenectomy. Transplantation, 49, 11001105.
  • Byrne, J.L., Beshti, H., Clark, D., Ellis, I., Haynes, A.P., Das-Gupta, E. & Russell, N.H. (2000) Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: evidence for a ‘graft vs. myelofibrosis’ effect. British Journal of Haematology, 108, 430433.
  • Campbell, P.J., Griesshammer, M., Dohner, K., Dohner, H., Kusec, R., Hasselbalch, H.C., Larsen, T.S., Pallisgaard, N., Giraudier, S., Le Bousse-Kerdiles, M.C., Desterke, C., Guerton, B., Dupriez, B., Bordessoule, D., Fenaux, P., Kiladjian, J.J., Viallard, J.F., Briere, J., Harrison, C.N., Green, A.R. & Reilly, J.T. (2006) V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood, 107, 20982100.
  • Cervantes, F. & Pereira, A. (2012) Prognostication in Primary Myelofibrosis. Current Hematologic Malignancy Reports, 7, 4349.
  • Cervantes, F., Rovira, M., Urbano-Ispizua, A., Rozman, M., Carreras, E. & Montserrat, E. (2000) Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect. Bone Marrow Transplantation, 26, 697699.
  • Cervantes, F., Dupriez, B., Pereira, A., Passamonti, F., Reilly, J.T., Morra, E., Vannucchi, A.M., Mesa, R.A., Demory, J.L., Barosi, G., Rumi, E. & Tefferi, A. (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood, 113, 28952901.
  • Ciurea, S.O., Sadegi, B., Wilbur, A., Alagiozian-Angelova, V., Gaitonde, S., Dobogai, L.C., Akard, L.P., Hoffman, R. & Rondelli, D. (2008) Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation. British Journal of Haematology, 141, 8083.
  • Ciurea, S.O., de Lima, M., Giralt, S., Saliba, R., Bueso-Ramos, C., Andersson, B.S., Hosing, C.M., Verstovsek, S., Champlin, R.E. & Popat, U. (2010) Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. Biology of Blood and Marrow Transplantation, 16, 555559.
  • Daly, A., Song, K., Nevill, T., Nantel, S., Toze, C., Hogge, D., Forrest, D., Lavoie, J., Sutherland, H., Shepherd, J., Hasegawa, W., Lipton, J., Messner, H. & Kiss, T. (2003) Stem cell transplantation for myelofibrosis: a report from two Canadian centers. Bone Marrow Transplantation, 32, 3540.
  • Deeg, H.J. & Appelbaum, F.R. (2011) Indications for and current results with allogeneic hematopoietic cell transplantation in patients with myelofibrosis. Blood, 117, 7185.
  • Deeg, H.J., Gooley, T.A., Flowers, M.E., Sale, G.E., Slattery, J.T., Anasetti, C., Chauncey, T.R., Doney, K., Georges, G.E., Kiem, H.P., Martin, P.J., Petersdorf, E.W., Radich, J., Sanders, J.E., Sandmaier, B.M., Warren, E.H., Witherspoon, R.P., Storb, R. & Appelbaum, F.R. (2003) Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood, 102, 39123918.
  • Devine, S.M., Hoffman, R., Verma, A., Shah, R., Bradlow, B.A., Stock, W., Maynard, V., Jessop, E., Peace, D., Huml, M., Thomason, D., Chen, Y.H. & van Besien, K. (2002) Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood, 99, 22552258.
  • Ditschkowski, M., Beelen, D.W., Trenschel, R., Koldehoff, M. & Elmaagacli, A.H. (2004) Outcome of allogeneic stem cell transplantation in patients with myelofibrosis. Bone Marrow Transplantation, 34, 807813.
  • Ditschkowski, M., Elmaagacli, A.H., Trenschel, R., Steckel, N.K., Koldehoff, M. & Beelen, D.W. (2006) No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis. Biology of Blood and Marrow Transplantation, 12, 13501351.
  • Dupriez, B., Morel, P., Demory, J.L., Lai, J.L., Simon, M., Plantier, I. & Bauters, F. (1996) Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood, 88, 10131018.
  • Ferrara, J.L., Levine, J.E., Reddy, P. & Holler, E. (2009) Graft-versus-host disease. Lancet, 373, 15501561.
  • Gangat, N., Caramazza, D., Vaidya, R., George, G., Begna, K., Schwager, S., Van Dyke, D., Hanson, C., Wu, W., Pardanani, A., Cervantes, F., Passamonti, F. & Tefferi, A. (2011) DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. Journal of Clinical Oncology, 29, 392397.
  • Guardiola, P., Anderson, J.E., Bandini, G., Cervantes, F., Runde, V., Arcese, W., Bacigalupo, A., Przepiorka, D., O'Donnell, M.R., Polchi, P., Buzyn, A., Sutton, L., Cazals-Hatem, D., Sale, G., de Witte, T., Deeg, H.J. & Gluckman, E. (1999) Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood, 93, 28312838.
  • Guglielmelli, P., Barosi, G., Specchia, G., Rambaldi, A., Lo Coco, F., Antonioli, E., Pieri, L., Pancrazzi, A., Ponziani, V., Delaini, F., Longo, G., Ammatuna, E., Liso, V., Bosi, A., Barbui, T. & Vannucchi, A.M. (2009) Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood, 114, 14771483.
  • Gupta, V., Kröger, N., Aschan, J., Xu, W., Leber, B., Dalley, C., Sabloff, M., Lipton, J.H., Messner, H. & Brune, M. (2009) A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis. Bone Marrow Transplantation, 44, 317320.
  • Hessling, J., Kröger, N., Werner, M., Zabelina, T., Hansen, A., Kordes, U., Ayuk, F.A., Renges, H., Panse, J., Erttmann, R. & Zander, A.R. (2002) Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia. British Journal of Haematology, 119, 769772.
  • Ho, V.T., Revta, C. & Richardson, P.G. (2008) Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies. Bone Marrow Transplantation, 41, 229237.
  • Hoffman, R. & Rondelli, D. (2007) Biology and Treatment of Primary Myelofibrosis. American Society of Haematology Educational Book, 34, 6354.
  • Hussein, K., Pardanani, A.D., Van Dyke, D.L., Hanson, C.A. & Tefferi, A. (2010) International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. Blood, 115, 496499.
  • Kalhs, P., Schwarzinger, I., Anderson, G., Mori, M., Clift, R.A., Storb, R., Buckner, C.D., Appelbaum, F.R., Hansen, J.A. & Sullivan, K.M. (1995) A retrospective analysis of the long-term effect of splenectomy on late infections, graft-versus-host disease, relapse, and survival after allogeneic marrow transplantation for chronic myelogenous leukemia. Blood, 86, 20282032.
  • Kerbauy, D.M., Gooley, T.A., Sale, G.E., Flowers, M.E., Doney, K.C., Georges, G.E., Greene, J.E., Linenberger, M., Petersdorf, E., Sandmaier, B.M., Scott, B.L., Sorror, M., Stirewalt, D.L., Stewart, F.M., Witherspoon, R.P., Storb, R., Appelbaum, F.R. & Deeg, H.J. (2007) Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biology of blood and marrow transplantation, 13, 355365.
  • Kroger, N., Badbaran, A., Holler, E., Hahn, J., Kobbe, G., Bornhauser, M., Reiter, A., Zabelina, T., Zander, A.R. & Fehse, B. (2007) Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood, 109, 13161321.
  • Kroger, N., Alchalby, H., Klyuchnikov, E., Badbaran, A., Hildebrandt, Y., Ayuk, F., Bacher, U., Bock, O., Kvasnicka, M., Fehse, B. & Zander, A. (2009b) JAK2-V617F- triggered pre-emptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. Blood, 113, 18661868.
  • Kröger, N., Zabelina, T., Schieder, H., Panse, J., Ayuk, F., Stute, N., Fehse, N., Waschke, O., Fehse, B., Kvasnicka, H.M., Thiele, J. & Zander, A. (2005) Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. British Journal of Haematology, 128, 690697.
  • Kröger, N., Holler, E., Kobbe, G., Bornhäuser, M., Schwerdtfeger, R., Baurmann, H., Nagler, A., Bethge, W., Stelljes, M., Uharek, L., Wandt, H., Burchert, A., Corradini, P., Schubert, J., Kaufmann, M., Dreger, P., Wulf, G.G., Einsele, H., Zabelina, T., Kvasnicka, H.M., Thiele, J., Brand, R., Zander, A.R., Niederwieser, D. & de Witte, T.M. (2009a) Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood, 114, 52645270.
  • Kröger, N., Klyuchnikov, E., Wolff, D., Bornhäuser, M., Kobbe, G., Nagler, A., Shimoni, A., Koenecke, C., Wolschke, C., Bacher, U. & Zander, A. (2010) Donor Lymphocyte Infusions and Second Transplantation as Salvage Treatment for Relapsed Myelofibrosis After Reduced-Intensity allografting. Blood (ASH Annual Meeting Abstracts), 116, Abstract 1300.
  • Li, Z., Gooley, T., Applebaum, F.R. & Deeg, H.J. (2001) Splenectomy and hemopoietic stem cell transplantation for myelofibrosis. Blood, 97, 21802181.
  • Lissandre, S., Bay, J.O., Cahn, J.Y., Porcher, R., Cacheux, V., Cabrespine, A., Cornillon, J., Cassinat, B., Peffault de Latour, R., Socie, G. & Robin, M. (2011) Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis. Bone Marrow Transplantation, 46, 557561.
  • Liu, H., Rich, E.S., Godley, L., Odenike, O., Joseph, L., Marino, S., Kline, J., Nguyen, V., Cunningham, J., Larson, R.A., Del Cerro, P., Schroeder, L., Pape, L., Stock, W., Wickrema, A., Artz, A.S. & van Besien, K. (2011) Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood, 118, 64386445.
  • Mascarenhas, J., Navada, S., Malone, A., Rodriguez, A., Najfeld, V. & Hoffman, R. (2010) Therapeutic options for patients with myelofibrosis in blast phase. Leukemia Research, 34, 12461249.
  • Mesa, R.A., Nagorney, D.S., Schwager, S., Allred, J. & Tefferi, A. (2006) Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer, 107, 361370.
  • Michallet, M., Corront, B., Bosson, J.L., Molina, L., Peissel, B., Maraninchi, D., Reiffers, J., Chabannon, C., Gaspard, M.H. & Stoppa, A.M. (1999) Role of splenectomy in incidence and severity of acute graft-versus-host disease: a multicenter study of 157 patients. Bone Marrow Transplantation, 8, 1317.
  • Nivison-Smith, I., Dodds, A.J., Butler, J., Bradstock, K.F., Ma, D.D., Simpson, J.M. & Szer, J. (2012) Allogeneic Hematopoietic Cell Transplantation for Chronic Myelofibrosis in Australia and New Zealand: older Recipients Receiving Myeloablative Conditioning at Increased Mortality Risk. Biology of Blood and Marrow Transplantation, 18, 302308.
  • Park, H.B., Oh, K., Garmaa, N., Seo, M.W., Byoun, O.J., Lee, H.Y. & Lee, D.S. (2010) CP-690550, a Janus kinase inhibitor, suppresses CD4+ T-cell-mediated acute graft-versus-host disease by inhibiting the interferon-γ pathway. Transplantation, 90, 825835.
  • Passamonti, F., Rumi, E., Pietra, D., Della Porta, M.G., Boveri, E., Pascutto, C., Vanelli, L., Arcaini, L., Burcheri, S., Malcovati, L., Lazzarino, M. & Cazzola, M. (2006) Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood, 107, 36763682.
  • Passamonti, F., Cervantes, F., Vannucchi, A.M., Morra, E., Rumi, E., Pereira, A., Guglielmelli, P., Pungolino, E., Caramella, M., Maffioli, M., Pascutto, C., Lazzarino, M., Cazzola, M. & Tefferi, A. (2010a) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood, 115, 17031708.
  • Passamonti, F., Rumi, E., Pietra, D., Elena, C., Boveri, E., Arcaini, L., Roncoroni, E., Astori, C., Merli, M., Boggi, S., Pascutto, C., Lazzarino, M. & Cazzola, M. (2010b) A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia, 24, 15741579.
  • Patriarca, F., Bacigalupo, A., Sperotto, A., Isola, M., Soldano, F., Bruno, B., van Lint, M.T., Iori, A.P., Santarone, S., Porretto, F., Pioltelli, P., Visani, G., Iacopino, P., Fanin, R. & Bosi, A. (2008) Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica, 93, 15141522.
  • Robin, M., Tabrizi, R., Mohty, M., Furst, S., Michallet, M., Bay, J.O., Cahn, J.Y., De Coninck, E., Dhedin, N., Bernard, M., Rio, B., Buzyn, A., Huynh, A., Bilger, K., Bordigoni, P., Contentin, N., Porcher, R., Socie, G. & Milpied, N. (2011) Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). British journal of Haematology, 152, 331339.
  • Rondelli, D., Barosi, G., Bacigalupo, A., Prchal, J.T., Popat, U., Alessandrino, E.P., Spivak, J.L., Smith, B.D., Klingemann, H.G., Fruchtman, S., Hoffman, R. & Myeloproliferative Diseases-Research Consortium (2005) Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood, 105, 41154119.
  • Rondelli, D., Boyer, M., Isola, L., Shore, T., Bacigalupo, A., Klisovic, R.B., Marchioli, R., Goldberg, J.D., Hoffman, R., Silverman, L.R. & Myeloproliferative Disorders Research Consortium (2010) First prospective study of allogeneic peripheral blood stem cell (PBSC) transplantation in patients with myelofibrosis in the United States: Interim analysis of MPD-RC 101 protocol. Journal of Clinical Oncology, 28, 15s. (suppl; abstr 6535)
  • Rumi, E., Passamonti, F., Arcaini, L., Bernasconi, P., Elena, C., Pietra, D., Brisci, A., Arbustini, E., Cazzola, M. & Lazzarino, M. (2010) Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. Bone Marrow Transplantation, 45, 798800.
  • Samuelson, S., Sandmaier, B.M., Heslop, H.E., Popat, U., Carrum, G., Champlin, R.E., Storb, R., Prchal, J.T., Gooley, T.A. & Joachim Deeg, H. (2011) Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age. British Journal of Haematology, 153, 7682.
  • Scott, B.L., Gooley, T., Linenberger, M., Sandmaier, B.M., Myerson, D., Chauncey, T., Appelbaum, F.R. & Deeg, H.J. (2010) International Working Group Scores Predict Post-Transplant Outcomes In Patients with Myelofibrosis. Blood (ASH Annual Meeting Abstracts), 114, 482483. Abstract 1175.
  • Scott, B.L., Gooley, T.A., Sorror, M.L., Rezvani, A.R., Linenberger, M.L., Grim, J., Sandmaier, B.M., Myerson, D., Chauncey, T.R., Storb, R., Buxhofer-Ausch, V., Radich, J.P., Appelbaum, F.R. & Deeg, H.J. (2012) The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Blood, doi 10.1182/blood-2011-08-372904. [Epub ahead of print]
  • Snyder, D.S., Palmer, J., Gaal, K., Stein, A.S., Pullarkat, V., Sahebi, F., Vora, N., Nakamura, R. & Forman, S.J. (2010) Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis. Biology of Blood and Marrow Transplantation, 16, 281286.
  • Sorror, M.L., Maris, M.B., Storb, R., Baron, F., Sandmaier, B.M., Maloney, D.G. & Storer, B. (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood, 106, 29122919.
  • Steckel, N.K., Koldehoff, M., Ditschkowski, M., Beelen, D.W. & Elmaagacli, A.H. (2007) Use of the activating gene mutation of the tyrosine kinase (VAL617Phe) JAK2 as a minimal residual disease marker in patients with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation. Transplantation, 83, 15181520.
  • Stewart, W.A., Pearce, R., Kirkland, K.E., Bloor, A., Thomson, K., Apperley, J., McQuaker, G., Marks, D.I., Craddock, C., McCann, S., Russell, N., Cook, G. & Kottaridis, P.D. (2010) The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study. Bone Marrow Transplantation, 45, 15871593.
  • Takagi, S., Ota, Y., Uchida, N., Takahashi, K., Ishiwata, K., Tsuji, M., Yamamoto, H., Asano-Mori, Y., Matsuno, N., Masuoka, K., Wake, A., Miyakoshi, S., Ohashi, K. & Taniguchi, S. (2010) Successful engraftment after reduced-intensity umbilical cord blood transplantation for myelofibrosis. Blood, 116, 649652.
  • Tefferi, A. (2010) Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis: the risk-benefit balancing act. Bone Marrow Transplantation, 45, 419421.
  • Tefferi, A. (2011) How I treat myelofibrosis. Blood, 117, 34943504.
  • Tefferi, A., Lasho, T.L., Schwager, S.M., Steensma, D.P., Mesa, R.A., Li, C.Y., Wadleigh, M. & Gary Gilliland, D. (2005) The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. British Journal of Haematology, 131, 320328.
  • Tefferi, A., Lasho, T.L., Schwager, S.M., Strand, J.S., Elliott, M., Mesa, R., Li, C.Y., Wadleigh, M., Lee, S.J. & Gilliland, D.G. (2006) The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer, 106, 631635.
  • Tefferi, A., Lasho, T.L., Huang, J., Finke, C., Mesa, R.A., Li, C.Y., Wu, W., Hanson, C.A. & Pardanani, A. (2008) Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia, 22, 756761.
  • Tefferi, A., Lasho, T.L., Abdel-Wahab, O., Guglielmelli, P., Patel, J., Caramazza, D., Pieri, L., Finke, C.M., Kilpivaara, O., Wadleigh, M., Mai, M., McClure, R.F., Gilliland, D.G., Levine, R.L., Pardanani, A. & Vannucchi, A.M. (2010a) IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia, 24, 13021309.
  • Tefferi, A., Lasho, T.L., Patnaik, M.M., Finke, C.M., Hussein, K., Hogan, W.J., Elliott, M.A., Litzow, M.R., Hanson, C.A. & Pardanani, A. (2010b) JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia, 24, 105109.
  • Tefferi, A., Vaidya, R., Caramazza, D., Finke, C., Lasho, T. & Pardanani, A. (2011) Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. Journal of Clinical Oncology, 29, 13561363.
  • Vannucchi, A.M., Antonioli, E., Guglielmelli, P., Rambaldi, A., Barosi, G., Marchioli, R., Marfisi, R.M., Finazzi, G., Guerini, V., Fabris, F., Randi, M.L., De Stefano, V., Caberlon, S., Tafuri, A., Ruggeri, M., Specchia, G., Liso, V., Rossi, E., Pogliani, E., Gugliotta, L., Bosi, A. & Barbui, T. (2007) Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood, 110, 840846.
  • Verstovsek, S., Kantarjian, H., Mesa, R.A., Pardanani, A.D., Cortes-Franco, J., Thomas, D.A., Estrov, Z., Fridman, J.S., Bradley, E.C., Erickson-Viitanen, S., Vaddi, K., Levy, R. & Tefferi, A. (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. New England Journal of Medicine, 363, 11171127.
  • Wong, K.M., Atenafu, E.G., Kim, D., Kuruvilla, J., Lipton, J.H., Messner, H.A. & Gupta, V. (2011) Incidence, Risk Factors for Early Hepatotoxicity and Its Impact on Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplantation. Blood (ASH Annual Meeting Abstracts), 118, Abstract 1951.